Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A novel approach for overcoming resistance in anticancer treatment

European Journal of Pharmacology

Volumn 667, Issue 1-3, 2011, Pages 56-65

  Tandon, Ruchi ^a   Kapoor, Shweta ^b,c   Vali, Shireen ^b,c   Senthil, V ^a   Nithya, D ^a   Venkataramanan, R ^a   Sharma, Ashish ^b,c   Talwadkar, Anay ^b,c   Ray, Abhijit ^a   Bhatnagar, Pradip K ^a   Dastidar, Sunanda G ^a  

^a RANBAXY LABORATORIES LTD   (India)

^b Cellworks Research India Pvt Ltd   (India)

^c CELLWORKS GROUP INC   (United States)

Author keywords

Cancer; EGFR (Epidermal growth factor receptor); IGF 1R (Insulin like growth factor receptor); Mutant cell line; Resistance; Signaling pathway

Indexed keywords

AEW 541; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N2 BENZOTHIAZOL 6 YL N4 (5 CYCLOPROPYL 1H PYRAZOL 3 YL) 6 METHYLPYRIMIDINE 2,4 DIAMINE; N4 (5 CYCLOPROPYL 1H PYRAZOL 3 YL) N2 (1H INDAZOL 5 YL) 5 METHYLPYRIMIDINE 2,4 DIAMINE; NVP AEW 541; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RESISTANCE; CELL ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; VALIDATION PROCESS;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1;

EID: 80052023098     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.04.066     Document Type: Article

References (29)

1. A. Arora, and E.M. Scholar Role of tyrosine kinase inhibitors in cancer therapy J. Pharmacol. Exp. Ther. 315 2005 971 979 (Pubitemid 41635382)
2. C.L. Arteaga Interference of the IGF system as a strategy to inhibit breast cancer growth Breast Cancer Res. Treat. 22 1992 101 106
3. J. Baselga The EGF receptor family as targets for breast cancer therapy Breast Cancer Res. 2 Suppl 1 2000 S13
4. R. Baserga The insulin-like growth factor 1 receptor: a key to tumor growth? Cancer Res. 55 1995 249 252
5. R. Baserga, F. Peruzzi, and K. Reiss IGF-1 receptor in cancer biology Int. J. Cancer 107 2003 873 877
6. A. Camirand, M. Zakikhani, F. Young, and M. Pollak Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib(Iressa) in human breast cancer cells Breast Cancer Res. 7 2005 R570 R579
7. A. Chakravarti, J.S. Loeffler, and N.J. Dyson Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res. 62 2002 200 207 (Pubitemid 34074005)
8. C.L. Chernicky, L. Yi, H. Tan, S.U. Gan, and J. Ilan Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential and prolongs survival in vivo Canc. Gene. Ther. 7 2000 384 395 (Pubitemid 30210405)
9. D. Cirstea, T. Hideshima, S. Rodig, L. Santo, S. Pozzi, S. Vallet, H. Ikeda, G. Perrone, G. Gorgun, K. Patel, N. Desai, P. Sportelli, S. Kapoor, S. Vali, S. Mukherjee, N.C. Munshi, K.C. Anderson, and N. Raje Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound- rapamycin and perifosine induces antitumor activity in multiple myeloma Mol. Cancer Ther. 2010 963 975
10. D. Coppola, A. Ferber, M. Miura, C. Sell, C. D'Ambrosio, R. Rubin, and R. Baserga A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor Mol. Cell. Biol. 14 1994 4588 4595 (Pubitemid 24196808)
11. S.E. Dunn, M. Ehrlich, N.J. Sharp, K. Reiss, G. Solomon, R. Hawkins, R. Baserga, and J.C. Barrett A dominant negative mutant of the insulin-like growth factor-1 receptor inhibits the adhesion, invasion and metastasis of breast cancer Cancer Res. 58 1998 3353 3361 (Pubitemid 28371076)
12. C. Garcia-Echeverria Medicinal chemistry approaches to target the kinase activity of IGF-1R IDrugs 9 2006 415 419 (Pubitemid 43862821)
13. K. Ghoreschi, A. Laurence, and J.J. O'Shea Selectivity and therapeutic inhibition of kinases: to be not to be? Nat. Immu. 10 2009 356 360
14. R.S. Heist, and D. Christiani EGFR-targeted therapies in lung cancer: predictors of response and toxicity Pharmacogenomics 10 2009 59 68
15. T. Holbro, and N.E. Hynes ErbB receptors: directing key signaling networks throughout life Annu. Rev. Pharmacol. Toxicol. 44 2004 195 217 (Pubitemid 38263839)
16. A. Hurbin, L. Dubrez, J.L. Coll, and M.C. Favrot Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines J. Bio. Chem. 277 2002 49127 49133 (Pubitemid 36014341)
17. S. KaulfuB, P. Burfeind, J. Gaedcke, and J.G. Scharf Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis Mol. Cancer Ther. 8 2009 821 833
18. D.S. Krause, and R.A. Van Etten Tyrosine kinases as targets for cancer therapy N. Engl. J. Med. 353 2005 172 187 (Pubitemid 41058349)
19. G.V. Kulkarni, W. Lee, A. Seth, and C.A. McCulloch Role of mitochondrial membrane potential in concanavalin A-induced apoptosis in human fibroblasts Exp. Cell Res. 245 1998 170 178 (Pubitemid 28551067)
20. P. Maiso, E.M. Ocio, M. Garayoa, J.C. Montero, F. Hofmann, C. García-Echeverría, J. Zimmermann, A. Pandiella, and J.F. San Miguel The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells Br. J. Haematol. 141 2007 470 482
21. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, and H. Varmus Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 2005 e73
22. P. Rajendran, H.T. Ong, L. Chen, F. Li, M. Shanmugam, S. Vali, T. Abbasi, S. Kapoor, A. Sharma, A.P. Kumar, K.M. Hui, and G. Sethi Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo Clin. Cancer Res. 17 2010 1425 1439
23. 1 monoclonal antibody to the insulin-like growth factor I receptor Clin. Cancer Res. 13 2007 5549s 5555s (Pubitemid 47510386)
24. D. Sachdev, S.L. Li, J.S. Hartell, Y. Fujita-Yamaguchi, J.S. Miller, and D. Yee A chimeric humanized single-chain antibody against the type I insulin like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I Cancer Res. 63 2003 627 635 (Pubitemid 36158140)
25. W.X. Tang, P.Y. Cheng, Y.P. Luo, and R.X. Wang Interaction between cisplatin, 5-fluorocil and vincristine on human hepatoma cell line (7721) World J. Gastroenterol. 4 1998 418 420
26. S. Vali, R. Pallavi, S. Kapoor, and U. Tatu Virtual prototyping study shows increased ATPase activity of Hsp90 to be the key determinant of cancer phenotype Syst. Synth. Biol. 4 2010 25 33
27. A.A. van de Loosdrecht, R.H. Beelen, G.J. Ossenkoppele, M.G. Broekhoven, and M.M. Langenhuijsen A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia J. Immuno. Method. 1994 174311 174320
28. J.L. Wilsbacher, Q. Zhang, L.A. Tucker, R.D. Hubbard, G.S. Sheppard, N.Y. Bamaung, S.D. Fidanze, G.T. Wang, X. Hu, S.K. Davidsen, R.L. Bell, and J. Wang Insulin-like growth factor-I receptor and erbb kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation J. Biol. Chem. 283 2008 23721 23730
29. F. Yamasaki, M.J. Johansen, D. Zhang, S. Krishnamurthy, E. Felix, C. Bartholomeusz, R.J. Aguilar, K. Kurisu, G.B. Mills, G.N. Hortobagyi, and N.T. Ueno Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt Cancer Res. 67 2007 5779 5788 (Pubitemid 46985011)